NIH halts funding for research using fetal tissue from elective abortions, shifting projects to alternatives

The National Institutes of Health has moved to end funding for research that uses human fetal tissue obtained from elective abortions, according to reporting. The policy change is expected to affect ongoing and future projects that relied on such tissue for certain kinds of biomedical studies. ([theguardian.com](https://www.theguardian.com/us-news/2026/jan/22/nih-human-fetal-tissue-abortion-research?utm_source=openai))

Researchers have long used fetal tissue in fields ranging from immunology to infectious disease and developmental biology, and many scientists argue it can be difficult to fully substitute in some experimental contexts. The new shift, NIH said, is aimed at modernizing research by promoting alternative technologies. ([theguardian.com](https://www.theguardian.com/us-news/2026/jan/22/nih-human-fetal-tissue-abortion-research?utm_source=openai))

The change reflects a revival of restrictions that were implemented during Trump’s earlier presidency and later lifted by the Biden administration in 2021. Under the updated approach, researchers may still be able to use tissue from miscarriages, but scientists have said elective-abortion tissue is often more viable for certain laboratory needs. ([theguardian.com](https://www.theguardian.com/us-news/2026/jan/22/nih-human-fetal-tissue-abortion-research?utm_source=openai))

Reporting noted that, in fiscal 2024, NIH funding tied to projects using fetal tissue amounted to tens of millions of dollars across dozens of projects. Critics of the policy say a sudden funding stop could interrupt experiments midstream, waste prior investment, and slow progress in areas where long-running tissue-based models have been foundational. ([theguardian.com](https://www.theguardian.com/us-news/2026/jan/22/nih-human-fetal-tissue-abortion-research?utm_source=openai))

Supporters of the decision argue it aligns federal biomedical funding with ethical concerns and with emerging methods such as organoids, advanced cell lines, and computational biology. In practice, the scientific impact will hinge on how quickly viable replacements can be validated and whether agencies create transition pathways that keep key research programs intact.

The broader public-health question is not abstract: fetal tissue research has historically contributed to medical knowledge that can translate into therapies and vaccines. As the funding landscape shifts, universities and labs may need to redesign protocols, renegotiate collaborations, and seek new sources of support — a process that can take months or years even for well-resourced institutions. ([theguardian.com](https://www.theguardian.com/us-news/2026/jan/22/nih-human-fetal-tissue-abortion-research?utm_source=openai))